In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.ads0633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Nadjet Gacem und 30 weiteren Autor:innen. Beteiligte Einrichtung: Paris Brain Institute - Institut du Cerveau (ICM), Sorbonne Université, Inserm, CNRS, Hôpital de la Pitié-Salpêtrière, AP-HP, 75013 Paris, France. Hauptthemen laut MEDLINE: Multiple Sclerosis, Computer Simulation. Die Arbeit nennt 97 Literaturangaben. Gefördert von: National Multiple Sclerosis Society, European Commission, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Current treatments for multiple sclerosis (MS) are insufficient to delay the neurodegenerative process that is the main cause of disability progression in patients with MS. Therapeutics aimed at supporting myelin regeneration and neuroprotection are thus a major unmet medical need for the progressive forms of MS. To address this, we developed a strategy combining in silico screening of more than 1500 repurposed compounds with a validation pipeline of models, encompassing rodent and human in vitro assays as well as mouse models of demyelination/remyelination. From the initial library, 273 drugs were prioritized in silico on the basis of the predicted effects on myelination and neuroprotection, and among them, 160 were potentially nontoxic. We identified 32 molecules that exerted a promyelinating and a neuroprotective action on rodent and human oligodendroglia and neurons. Our data identified classes of compounds with potentially distinct mechanisms of action that may foster remyelination and neuroprotection. The therapeutic activity of one selected drug, the histamine receptor H3 antagonist bavisant, was further validated in mouse models of demyelination and axonal injury reproducing some key pathological features occurring in MS. Our in vivo studies demonstrated that bavisant promoted remyelination and neuroprotection when administered to LPC-treated, cuprizone-fed, or MOG-induced EAE mice, as well as in a human oligodendroglia chimeric mouse model of demyelination/remyelination. These findings provide proof-of-concept validation for bavisant as a candidate for neuroprotective clinical trials in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paris Brain Institute - Institut du Cerveau (ICM), Sorbonne Université, Inserm, CNRS, Hôpital de la Pitié-Salpêtrière, AP-HP, 75013 Paris, France.
- Division of Neuroscience, Vita-Salute San Raffaele University, Institute of Experimental Neurology, IRCCS San Raffaele Scientific Institute, 20129 Milan, Italy.
- Institute of Neuropathology, University Hospital Münster, 48149 Münster, Germany.
- Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA.
- Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
- Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.
ORCID-Profile: Nadjet Gacem, Svetlana Bezukladova, Tala Karam, Elena Brambilla, Francesca Ruffini, Beatriz Garcia-Diaz, Marion J F Levy, Qiao-Ling Cui, Alessia Formato, Stefanie Albrecht, Elif Nur Yilmaz, Raquel Guerrero González, Ivano Eberini, Stefania Olla, Alberto Bresciani, Norbert Goebels, Frauke Zipp, Cristina Agresti, Jack Antel, Anne Baron-Van Evercooren, Sergio E Baranzini, Paola Panina-Bordignon, Brahim Nait-Oumesmar, Gianvito Martino
Förderung
- National Multiple Sclerosis Society
- European Commission
- Agence Nationale de la Recherche
- US National Institutes of Health
- US National Science Foundation
- Interdisciplinary Center for Clinical Research
- German Research Foundation DFG
- International Progressive MS Alliance – Collaborative Network Award BRAVEinMS,
Zitieren
APA
Gacem, N., Bezukladova, S., Windener, F., Karam, T., Ottoboni, L., Brambilla, E., Ruffini, F., Soman, K., Garcia-Diaz, B., Levy, M. J. F., Cui, Q. L., Formato, A., Deboux, C., Chazot, J., Panic, R., Albrecht, S., Yilmaz, E. N., González, R. G., Eberini, I., …, & Martino, G. (2026). In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ads0633
Vancouver
Gacem N, Bezukladova S, Windener F, Karam T, Ottoboni L, Brambilla E, et al. In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.ads0633
BibTeX
@article{Gacem2026,
author = {Gacem, Nadjet and Bezukladova, Svetlana and Windener, Farina and Karam, Tala and Ottoboni, Linda and Brambilla, Elena and Ruffini, Francesca and Soman, Karthik and Garcia-Diaz, Beatriz and Levy, Marion J F and Cui, Qiao-Ling and Formato, Alessia and Deboux, Cyrille and Chazot, Jeremy and Panic, Radmila and Albrecht, Stefanie and Yilmaz, Elif Nur and González, Raquel Guerrero and Eberini, Ivano and Olla, Stefania and Bresciani, Alberto and Goebels, Norbert and Zipp, Frauke and Agresti, Cristina and Antel, Jack and Evercooren, Anne Baron-Van and Kuhlmann, Tanja and Baranzini, Sergio E and Panina-Bordignon, Paola and Nait-Oumesmar, Brahim and Martino, Gianvito},
title = {In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.ads0633}
}
EUVIMED